The Mounjaro Blog: What Clinical Evidence Really Tells Us

The SURMOUNT trial data: what the numbers actually mean

The headline figure from SURMOUNT-1, published in the New England Journal of Medicine, is an average weight reduction of around 20–21% over 72 weeks at the 15mg dose. That is a population average across 2,539 adults, individual results varied considerably above and below it, and the trial ran alongside a reduced-calorie diet and increased physical activity. Quoting that number without those caveats misrepresents what tirzepatide actually does.

The other headline worth understanding is the SURMOUNT-5 result. In a direct head-to-head trial against semaglutide 2.4mg (the standard Wegovy maintenance dose at the time), tirzepatide produced greater average weight reduction over 72 weeks in adults with obesity and no diabetes. NICE's appraisal of tirzepatide (TA1026, published December 2024) noted that indirect comparisons broadly support that finding, though it was careful to frame it as a comparison of populations and trial designs, not a simple ranking. If you want to explore how the two medicines compare, our weight-loss treatment overview covers the licensed options side by side.

What this means practically: the trial data supports tirzepatide as the most effective single agent currently licensed in the UK for weight management. It does not mean everyone will lose 20%. It does not mean results arrive quickly at 2.5mg. And it does not tell you whether tirzepatide is the right choice for your health picture, that is a prescriber's call. If you would like to read more around the topic, our Mounjaro blogs cover a range of questions that come up regularly from people considering or already on treatment.

How the licensed doses actually work in sequence

Mounjaro comes in six UK strengths: 2.5, 5, 7.5, 10, 12.5 and 15mg. Each pen delivers four weekly doses. Treatment starts at 2.5mg not because it produces meaningful weight loss at that level, but because it gives your gut time to adjust to a mechanism that slows gastric emptying significantly. Most people who experience nausea on GLP-1 or dual-agonist medicines find it peaks in those first few weeks and then settles.

Titration (moving up to the next strength) typically happens in four-week steps and is always directed by the prescriber, not by a fixed calendar. If side effects are uncomfortable at a given dose, staying there longer before stepping up is a legitimate clinical decision. Our tirzepatide information page goes into the mechanism in more detail for those who want the biochemistry.

One practical detail that comes up regularly: the pens need to live in the fridge, between 2°C and 8°C. The exact window for keeping a pen at room temperature before use is specified in the Patient Information Leaflet; check yours rather than relying on a number from a blog post. The SmPC on the Electronic Medicines Compendium is the reference point if you want the formal wording.

Side effects: what the evidence says and when to act

The most common side effects across the SURMOUNT programme were gastrointestinal: nausea, diarrhoea, vomiting, constipation and indigestion appearing with some frequency, particularly after starting or after each step-up. They are generally described as mild to moderate and transient. That matches what the NHS's tirzepatide medicines page reports, and it is consistent with what clinicians see in practice.

The side effect that needs a clear signal here is pancreatitis. The MHRA issued a Drug Safety Update in January 2026 specifically addressing acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines. Severe, persistent stomach pain that radiates to the back (with or without vomiting) warrants urgent medical attention, not a wait-and-see approach. There are also rarer signals around gallbladder symptoms and, in people with type 2 diabetes, diabetic retinopathy changes. None of these are reasons to avoid treatment if it is clinically appropriate; they are reasons to be informed and to have a prescriber who knows your history. If you donate blood and are wondering how treatment might affect that, our page on Mounjaro and giving blood explains what the current guidance says.

Questions about bloating specifically come up often in search. Our Mounjaro bloat page addresses that symptom in detail, including what tends to help and when it warrants a clinical conversation.

NHS access, private routes, and what eligibility actually looks like

NICE TA1026 recommends tirzepatide for adults with a BMI of 35 or above and at least one qualifying weight-related condition, high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the threshold is 2.5 kg/m² lower. NHS rollout is phased and prioritises those with the highest clinical need first; Cohort 2 (BMI 35–39.9 with four or more conditions) began in June 2026.

For people who do not meet current NHS criteria or do not want to wait, private prescription through a GPhC-registered pharmacy is the legal alternative. The private licensed eligibility follows the Mounjaro SmPC: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. BMI alone does not guarantee approval; the prescriber considers the full clinical picture. If you are looking at the cost side of private treatment, our Mounjaro pricing page explains how market pricing works and what a legitimate single price should include.

If you have further questions about how the consultation works or what to expect at each stage, our FAQs cover the most common ones. When you are ready to have your eligibility assessed properly, speaking to our prescribers is the straightforward next step.